$CERT News

Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026

Certara (CERT) Stock May Trade Above Fair Value On Its 75% Slump

Keybanc Maintains Overweight on Certara, Raises Price Target to $12

Certara: Software Bookings Are Improving, But Cash Flow Has Yet To Follow

TD Cowen Maintains Buy on Certara, Raises Price Target to $11

Barclays Maintains Equal-Weight on Certara, Raises Price Target to $9

In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.

UBS Downgrades Certara to Neutral, Maintains Price Target to $10

Certara (CERT) Slashes Jobs While Doubling Down On Software Growth

The Bull Case For Certara (CERT) Could Change Following Wider Q2 Loss And Leadership Shake-Up - Learn Why

Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5

Certara (CERT) Q2 2026 Earnings Call Transcript

Certara, Inc. Q2 2026 Earnings Call Summary

Certara, Inc. 2026 Q2 - Results - Earnings Call Presentation

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

Certara Q2 Earnings Call Highlights

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara Reports Second Quarter 2026 Financial Results

Transcript: Certara Q2 2026 Earnings Conference Call

Certara Lowers FY2026 Adj EPS Guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 Est; Lowers FY2026 Sales Guidance from $395.000M-$405.000M to $367.000M-$382.000M vs $398.585M Est